Bhatnagar, A., Marin, M. P., Lischalk, J. W., Koh, M. J., Agazzi, S., Suy, S., Harris, B. T., Sharma, S. T., Aulisi, E., Anaizi, A., Khattab, M. H., Jean, W. C., Collins, S. P., & Collins, B. T. (2025). Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1519445

Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

Diaz, M., & Pan, P. C. (2025). Management of Low-Grade Gliomas. The Cancer Journal, 31(1). https://doi.org/10.1097/ppo.0000000000000760

Mendez, J. S., Cohen, A. L., Eckenstein, M., Jensen, R. L., Burt, L. M., Salzman, K. L., Chamberlain, M., Hsu, H. H., Hutchinson, M., Iwamoto, F., Ligon, K. L., Mrugala, M. M., Pelayo, M., Plotkin, S. R., Puduvalli, V. K., Raizer, J., Reardon, D. A., Sterba, M., Walbert, T., … Colman, H. (2024). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdae202

Mrugala, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024). Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022. Journal of Neuro-Oncology, 169(1), 25–38. https://doi.org/10.1007/s11060-024-04682-7

Ellingson, B. M., Sanvito, F., Cloughesy, T. F., Huang, R. Y., Villanueva-Meyer, J. E., Pope, W. B., Barboriak, D. P., Shankar, L. K., Smits, M., Kaufmann, T. J., Boxerman, J. L., Weller, M., Galanis, E., Groot, J. de, Gilbert, M. R., Lassman, A. B., Shiroishi, M. S., Nabavizadeh, A., Mehta, M., … Wen, P. Y. (2024). A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults. American Journal of Neuroradiology, ajnr.A8396. https://doi.org/10.3174/ajnr.a8396

Gallitto, M., Pan, P. C., Chan, M. D., Milano, M. T., & Wang, T. J. C. (2024). The role of radiotherapy in immunotherapy strategies in the central nervous system. Neuro-Oncology, 26(Supplement_1), S66–S75. https://doi.org/10.1093/neuonc/noad184

Diaz, M., Chudsky, S., Pentsova, E., & Miller, A. M. (2024). Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. Translational Oncology, 41, 101881. https://doi.org/10.1016/j.tranon.2024.101881

Rahman, R., Trippa, L., Lee, E. Q., Arrillaga-Romany, I., Fell, G., Touat, M., McCluskey, C., Wiley, J., Gaffey, S., Drappatz, J., Welch, M. R., Galanis, E., Ahluwalia, M. S., Colman, H., Nabors, L. B., Hepel, J., Elinzano, H., Schiff, D., Chukwueke, U. N., … Wen, P. Y. (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of Clinical Oncology, 41(36), 5524–5535. https://doi.org/10.1200/jco.23.00493

Shi, W., Glas, M., Mrugala, M. M., Iwamoto, F. M., Lukas, R. V., Palmer, J., & Suh, J. (2023). 529P Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022. Annals of Oncology, 34, S402. https://doi.org/10.1016/j.annonc.2023.09.1723

Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., Huang, R., Lassman, A. B., Mehta, M., Molinaro, A. M., Preusser, M., Rahman, R., Shankar, L. K., Stupp, R., Villanueva-Meyer, J. E., … Chang, S. M. (2023). RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Journal of Clinical Oncology, 41(33), 5187–5199. https://doi.org/10.1200/jco.23.01059

Mrugala, M. M., Shi, W., Iwamoto, F. M., Heidemann, M., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). LONG-TERM POST-MARKETING SURVEILLANCE DATA FROM ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY. Neuro-Oncology, 25(Supplement_3), iii2–iii2. https://doi.org/10.1093/neuonc/noad147.007

Ellingson, B. M., Wen, P. Y., Chang, S. M., van den Bent, M., Vogelbaum, M. A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A. B., Gilbert, M. R., de Groot, J. F., Weller, M., Galanis, E., & Cloughesy, T. F. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 25(6), 1017–1028. https://doi.org/10.1093/neuonc/noad002

Mrugala, M. M., Shi, W., Iwamoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022. Neuro-Oncology, 25(Supplement_1), i80–i80. https://doi.org/10.1093/neuonc/noad073.310

Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., Gan, H. K., Lin, N. U., Lassman, A. B., Wen, P. Y., Weller, M., van den Bent, M., & Preusser, M. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 20(6), 372–389. https://doi.org/10.1038/s41571-023-00756-z

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research, 1030–1043. Portico. https://doi.org/10.1159/000531142

Carneiro, B. A., Papadopoulos, K. P., Strickler, J. H., Lassman, A. B., Waqar, S. N., Chae, Y. K., Patel, J. D., Shacham-Shmueli, E., Kelly, K., Khasraw, M., Bestvina, C. M., Merrell, R., Huang, K., Atluri, H., Ansell, P., Li, R., Jin, J., Anderson, M. G., Reilly, E. B., … Gan, H. K. (2022). Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdac183

Kumthekar, P. U., Avram, M. J., Lassman, A. B., Lin, N. U., Lee, E., Grimm, S. A., Schwartz, M., Bell Burdett, K. L., Lukas, R. V., Dixit, K., Perron, I., Zhang, H., Gradishar, W. J., Pentsova, E. I., Jeyapalan, S., Groves, M. D., Melisko, M., & Raizer, J. J. (2022). A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncology, 25(3), 557–565. https://doi.org/10.1093/neuonc/noac195

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., … Mehta, M. P. (2022). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339–350. https://doi.org/10.1093/neuonc/noac173

Rudà, R., Capper, D., Waldman, A. D., Pallud, J., Minniti, G., Kaley, T. J., Bouffet, E., Tabatabai, G., Aronica, E., Jakola, A. S., Pfister, S. M., Schiff, D., Lassman, A. B., Solomon, D. A., Soffietti, R., Weller, M., Preusser, M., Idbaih, A., Wen, P. Y., & van den Bent, M. J. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncology, 24(12), 2015–2034. https://doi.org/10.1093/neuonc/noac188

Iwamoto, F., Gondi, V., Butowski, N., Falchook, G., Williams, A., Peters, K. B., Evans, J., Lakhani, N., McKean, M., Symeonides, S., Ellingson, B., Rotolo, J., Capiaux, G., Wiegert, E., Michel, R., Kaesshaefer, S., & Bexon, A. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii83–vii83. https://doi.org/10.1093/neuonc/noac209.314

Mrugala, M., Shi, W., Iwamoto, F., Lukas, R., Palmer, J., Suh, J., & Glas, M. (2022). INNV-07. TUMOR TREATING FIELDS (TTFIELDS; 200 KHZ) POST-MARKETING SAFETY DATA FROM PATIENTS WITH GLIOBLASTOMA TREATED BETWEEN 2011–2022. Neuro-Oncology, 24(Supplement_7), vii142–vii142. https://doi.org/10.1093/neuonc/noac209.547

Yuen, C., Pan, P., Teasley, D., Miller, M., Sun, Y., Canoll, P., Joanta-Gomez, A., Bargo, A., & Iwamoto, F. (2022). PATH-32. CONCORDANCE FOR CDKN2A/B LOSS AND TERT MUTATION IN WHO 2021 CLASSIFICATION GRADE 3 MENINGIOMAS: A RETROSPECTIVE STUDY. Neuro-Oncology, 24(Supplement_7), vii157–vii157. https://doi.org/10.1093/neuonc/noac209.605

Iwamoto, F., Tanguturi, S., Desai, A., Nayak, L., Uhlmann, E., Wang, T., Lustig, R., Hertan, L., Bagley, S., Hayden, J., Laforest-Roys, C., Muzikansky, A., McCluskey, C., Chukwueke, U., McFaline-Figueroa, J. R., Lee, E., Wen, P. Y., & Reardon, D. (2022). CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723). Neuro-Oncology, 24(Supplement_7), vii63–vii64. https://doi.org/10.1093/neuonc/noac209.250

Castro, M., Iwamoto, F., Ahluwalia, M., Usmani, S., Kumar, A., Kapoor, S., Suseela, R. P., Kulkarni, S., Mohanty, J., Shyamasundar, V., Ghosh, A., Prasad, N., Patil, M., Choudhury, S. R., Chauhan, J., Sauban, M., Joseph, V., Kumari, P., Mitra, U., … Basu, S. (2022). EPCO-06. THE IMPACT OF MISMATCH REPAIR DEFICIENCY (MMRD) ON SURVIVAL OF TEMOZOLOMIDE (TMZ)-TREATED PATIENTS WITH MGMT METHYLATED (M-MGMT) GLIOBLASTOMA (GBM): A CELLWORKS COMPUTATIONAL BIOSIMULATION PILOT STUDY. Neuro-Oncology, 24(Supplement_7), vii116–vii117. https://doi.org/10.1093/neuonc/noac209.441

Spinazzi, E. F., Argenziano, M. G., Upadhyayula, P. S., Banu, M. A., Neira, J. A., Higgins, D. M. O., Wu, P. B., Pereira, B., Mahajan, A., Humala, N., Al-Dalahmah, O., Zhao, W., Save, A. V., Gill, B. J. A., Boyett, D. M., Marie, T., Furnari, J. L., Sudhakar, T. D., Stopka, S. A., … Bruce, J. N. (2022). Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet Oncology, 23(11), 1409–1418. https://doi.org/10.1016/s1470-2045(22)00599-x

Bagley, S., Polley, M.-Y., Kotecha, R., Brem, S., Tolakanahalli, R., Iwamoto, F., Gilbert, M., Won, M., & Mehta, M. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS. Neuro-Oncology, 24(Supplement_7), vii64–vii64. https://doi.org/10.1093/neuonc/noac209.253

Wen, P. Y., Reardon, D. A., Forst, D., Lee, E., Daoud, T., Berthoud, T., Soare, C., Diaz-Mitoma, F., Anderson, D. E., Lassman, A., & Iwamoto, F. (2022). CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology, 24(Supplement_7), vii62–vii62. https://doi.org/10.1093/neuonc/noac209.246

Liau, L. M., Ashkan, K., Brem, S., Campian, J., Trusheim, J., Iwamoto, F., Tran, D., Anstass, G., Cobbs, C., Heth, J., Salacz, M., D’Andre, S., Aiken, R., Moshel, Y., Nam, J., Pillainayagam, C., Wagner, S., Walter, K., Chaudary, R., … Bosch, M. (2022). CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. Neuro-Oncology, 24(Supplement_7), vii66–vii66. https://doi.org/10.1093/neuonc/noac209.259

Iwamoto, F., Polley, M.-Y., Shaw, E., Buckner, J., Barger, G., Coons, S., Ricci, P., Gilbert, M., Brown, P., Stelzer, K., Rogers, C. L., Suh, J., Schultz, C., Howard, S., Fisher, B., Kim, M., Huang, J., Haddock, M., Won, M., & Mehta, M. (2022). CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT. Neuro-Oncology, 24(Supplement_7), vii73–vii73. https://doi.org/10.1093/neuonc/noac209.282

Pan, P., Haggiagi, A., & Iwamoto, F. (2022). BIOM-12. PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii6–vii6. https://doi.org/10.1093/neuonc/noac209.022

Peereboom, D., Lindsay, R., Badruddoja, M., Nabors, L. B., Kumthekar, P., Lieberman, F., Tran, D., Phuphanich, S., Schiff, D., Sherman, J., Butowski, N., Dunbar, E., Fink, K., Iwamoto, F., Moertel, C., Schulder, M., Walbert, T., Habboubi, N., Grzegorzewski, K., … Reardon, D. A. (2022). CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL. Neuro-Oncology, 24(Supplement_7), vii67–vii67. https://doi.org/10.1093/neuonc/noac209.261

Bunevicius, A., Donovan, L., & Sheehan, J. (2022). Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review. Journal of Neuro-Oncology, 159(2), 319–331. https://doi.org/10.1007/s11060-022-04067-8

Lassman, A. B., Hoang-Xuan, K., Polley, M.-Y. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., Souhami, L., Dinjens, W. N. M., Laack, N. N., Kouwenhoven, M. C. M., Fink, K. L., French, P. J., Macdonald, D. R., Lacombe, D., Won, M., Gorlia, T., Mehta, M. P., & van den Bent, M. J. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 40(23), 2539–2545. https://doi.org/10.1200/jco.21.02543

Ellingson, B. M., Gerstner, E. R., Lassman, A. B., Chung, C., Colman, H., Cole, P. E., Leung, D., Allen, J. E., Ahluwalia, M. S., Boxerman, J., Brown, M., Goldin, J., Nduom, E., Hassan, I., Gilbert, M. R., Mellinghoff, I. K., Weller, M., Chang, S., Arons, D., … Cloughesy, T. F. (2022). Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 24(8), 1219–1229. https://doi.org/10.1093/neuonc/noac086

Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil-Gil, M. J., Puduvalli, V. K., Raizer, J. J., De Vos, F. Y. F., Wen, P. Y., Butowski, N. A., Clement, P. M. J., Groves, M. D., Belda-Iniesta, C., Giglio, P., Soifer, H. S., Rowsey, S., Xu, C., Avogadri, F., Wei, G., Moran, S., & Roth, P. (2022). Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clinical Cancer Research, 28(11), 2270–2277. https://doi.org/10.1158/1078-0432.ccr-21-2664

Yuen, C. A., Barbaro, M., & Haggiagi, A. (2022). Newly Diagnosed Glioblastoma in Elderly Patients. Current Oncology Reports, 24(3), 325–334. https://doi.org/10.1007/s11912-022-01201-7

Lassman, A. B., Wen, P. Y., van den Bent, M. J., Plotkin, S. R., Walenkamp, A. M. E., Green, A. L., Li, K., Walker, C. J., Chang, H., Tamir, S., Henegar, L., Shen, Y., Alvarez, M. J., Califano, A., Landesman, Y., Kauffman, M. G., Shacham, S., & Mau-Sørensen, M. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 28(3), 452–460. https://doi.org/10.1158/1078-0432.ccr-21-2225

Barbaro, M., Blinderman, C. D., Iwamoto, F. M., Kreisl, T. N., Welch, M. R., Odia, Y., Donovan, L. E., Joanta-Gomez, A. E., Evans, K. A., & Lassman, A. B. (2022). Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. Neurology, 98(3). https://doi.org/10.1212/wnl.0000000000013057

Griguer, C. E., Oliva, C. R., Coffey, C. S., Cudkowicz, M. E., Conwit, R. A., Gudjonsdottir, A. L., Ecklund, D. J., Fedler, J. K., Neill-Hudson, T. M., Nabors, L. B., Benge, M., Hackney, J. R., Chase, M., Leonard, T. P., Patel, T., Colman, H., de la Fuente, M., Chaudhary, R., Marder, K., … Markert, J. (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdab186

Agopyan-Miu, A. H. C. W., Banu, M. A., Miller, M. L., Troy, C., Hargus, G., Canoll, P., Wang, T. J. C., Feldstein, N., Haggiagi, A., & McKhann, G. M. (2021). Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report. Acta Neuropathologica Communications, 9(1). https://doi.org/10.1186/s40478-021-01265-9